Introduction
Candida spp. are important opportunist pathogens that infect medically compromised individuals. The most common oral disease caused by Candida spp. is denture stomatitis. Although all species of Candida can produce denature stomatitis, the most commonly isolated species is C. albicans [l] . C. albicans is the commonest of the Candida spp. found within the oral cavity; other species that have been isolated include C. glabrata, C. tropicalis, C. guilliermondii and C. krusei [2] . However, if Candida spp. enter the blood stream, they can cause severe life-threatening diseases such as infective endocarditis, vascular catheter sepsis and infections of vascular prostheses [3, 41. Several species of Candida have been isolated from patients with endocarditis, with C. albicans being the most common, followed by C. parapsilosis, C. tropicalis, C. stellatoidia (currently classified in the species C. albicans) and C. krusei [l, 5, 61. The mechanisms utilised by Candida spp. to initiate vascular infections are believed to be complex, involving interactions of fungal cells with plasma proteins, e.g., fibronectin [7] , endothelial cells [8] and platelets [9] , and avoidance of plasma host defences such as complement and phagocytosis. It is well known that Candida cells can activate the alternative complement pathway, a major effector pathway of inflammation, and this will release the inflammatory mediators C3a which is vasodilatory, and C5a which activates and recruits white blood cells to sites of infection. Recently, it has been demonstrated that activation of complement on the surface of Streptococcus sanguis may be involved in platelet aggregation [lo] . Activation of white blood cells, e.g., polymorphonuclear leucocytes (PMNLs), macrophages, mast cells and platelets also releases inflammatory mediators, e.g., histamine and arachidonic acid metabolites and antimicrobial peptides such as human neutrophil peptides [ 1 1, 121 and platelet microbicidal proteins [13] . It has been clearly demonstrated that PMNLs are of vital importance in preventing the development of candidosis [14] . The aim of this investigation was to examine different species of Candida for their ability to interact with these elements of the host defence system.
Materials and methods

Candida strains and growth conditions
All strains were obtained from the culture collection of the Institute of Dental Research, Sydney, Australia. C. albicans NCYC 1473 (GRI 682) was originally isolated from a cervical smear, C. albicans NCYC 1467 (GDH 2346) was isolated from the mouth of a patient with denture stomatitis, C. albicans Y5499 and C. albicans (formerly stellatoidia) Y523, C. tropicalis Y9, C. parapsilosis Y316, C. krusei Y301, C. kefir Y83 and C. guilliermondii Y324 were all isolated from the saliva of patients attending the United Dental Hospital of Sydney. All strains were grown for 24 h in Sabouraud's broth (containing Neopeptone 10 g/L, glucose 40 g/L; pH 5.6), cells were harvested by Centrifugation (1 0 min, 3000 g), washed three times in phosphate-buffered saline (PBS; NaCl 8.0 g/L, KCl 0.2 g/L, Na2HP04 1.15 g/L, KH2P04 0.2 g/L, pH 7.4) and finally resuspended in PBS to an OD600 of 1.0 (1.5 X lo6 cfu/ml), unless otherwise stated.
Interactions of Candida cells with platelets
Two methods were used to assess the interaction of Candida cells with platelets. Firstly, the ability of Candida spp. to aggregate platelets was measured and secondly the ability of platelet-rich plasma (PRP) to kill Candida spp. was determined. PRP was obtained from whole citrated blood by centrifugation for 10 min at 250 g and removal of the supernate. Platelet-poor plasma (PPP) was obtained by recentrifugation of the pellet from the PRP for 10 min at 3000 g and removal of the supernate.
For examination of the ability of Candida spp. to aggregate platelets, Candida cells were mixed with platelets (2.5 X lo8 platelets/ml) in differing ratios of Candida cells to platelets, ranging from 1:lOOO to l:lO, by concentration of the Candida cells by centrifugation, or dilution of the cells in PBS. In either a single-channel recording platelet aggregometer (Model 430; Chrono-log Corporation, Havertown, PA, USA) or a dual-channel aggregometer (Model 540), Candida cells and platelets were mixed and allowed to interact at 37°C for 25 min. Aggregation was recorded as a drop in the OD. Adenosine diphosphate (ADP), a natural agonist, was added after incubation for 22 min to measure platelet function and also the degree of aggregation caused by Candida spp.
Potential inhibitors (Sigma Aldrich, Sydney, Australia) were dissolved in PBS and added to plasma to the following final concentrations: 40 mM disodium ethylene-diamine-tetra-acetic acid (EDTA), apyrase (grade v) 10 mg/mL, 1 mM quinacrine or 2 mM imipramine.
The inhibitors (25 pl) were added to both PPP and PRP, incubated at ambient temperature for 10 min and then incubated at 37°C for 5 rnin before the addition of Candida cells. Platelet aggregation was then measured. The control consisted of 25 pl of PBS. An examination of the ability of platelets obtained from different blood group subjects was also performed, with subjects who were A positive, A negative, B positive, 0 negative, 0 positive and AB negative.
For examination of the ability of platelets to kill Candida spp., PRP and Candida cells were mixed in the optimal ratio for platelet aggregation and incubated at 37°C for 4 h with end-over-end rotation. At time 0 and after 30 min, 1 h and 4 h, samples of the mixture were removed and a Miles and Misra plate assay [15] was performed to determine the number of viable Candida cfu. In addition, the numbers of yeast cells in clumps of yeast plus platelets was examined microscopically and this number was taken into account when the numbers of viable c h were calculated in the Miles and Misra assay.
Interaction of Candida spp. with complement
Cells were allowed to interact with complement in two ways. Firstly, the ability of complement in serum to kill Candida cells was measured and secondly the ability of Candida cells to bind to complement component C3 was examined.
For determination of complement susceptibility, Candida cells were resuspended to an OD600 of 1.0 in Dulbecco's phosphate-buffered saline (CSL, Sydney, Australia) and then mixed with pooled normal human serum (obtained from four healthy donors) to give a final concentration of 50% serum. The mixtures were allowed to interact together at 35°C for 4 h with endover-end rotation; samples were removed at times 0, 30 min, 1 h and 4 h after incubation. A Miles and Misra plate assay was then performed to determine the number of viable Candida cfu.
For examination of the binding and activation of complement C3 by Candida strains, the method of Gordon et al. [16] was used. Briefly, Candida cells were opsonised in serum 50% for 1 h at 35"C, then washed three times in PBS containing sodium dodecylsulphate (SDS) 1% w/v. Pellets were then resuspended in a solution of 1 M hydroxylamine/SDS 1% and incubated for 1 h at 37°C. The Candida cells were then removed by centrifugation and the supernate containing C3 fragments was collected and stored at -70°C. Before separation of C3 fragments by SDS-PAGE, C3 fragments were reduced by boiling with 10 mM dithiothreitol for 10 min. SDS-PAGE was then performed with prepoured 4-20% gradient gels (BioRad, Sydney, Australia). The separated proteins were then transferred to nitrocellulose membranes by Western blotting in Towbin's buffer. The membrane was blocked for 2 h in bovine serum albumin (Sigma Aldrich) 1% w/v in PBS containing Tween 20 0.05% v/v. Subsequently, a 1 in 100 dilution of sheep antiserum to human C3c (The Binding Site; Birmingham) in PBS containing Tween 20 0.05% (PBST) was added to the membrane and incubated at ambient temperature for 4 h. After washing three times in PBST, peroxidase-conjugated sheep antiserum to rabbit IgG (Sigma Aldrich; 1 in 500 dilution) was added and incubated for 1 h at ambient temperature. The nitrocellulose was then washed three times in PBS and developed with chloronaphthol (Sigma Aldrich) 12 mg in methanol 25% v/v and H202 0.001% v/v in PBS.
Survival of Candida spp. in the presence of PMNLS
Whole blood was collected in sodium heparin-treated Vacuettes (Greiner GesmbH, Kremsmunster, Austria) and separated with mono-poly resolving medium according to the manufacturer's instructions (ICN Biomedicals, Sydney, Australia). Briefly, 7 ml of blood was layered on 6ml of mono-poly resolving medium and centrifuged at 400 g for 45 min. Red blood cells were centrifuged through the mono-poly resolving medium, leaving monocytes and PMNLs in two distinct bands; PMNLs were the pipetted off with a sterile disposable Pasteur pipette. Purified PMNLs were washed three times by centrifugation at 250 g in PBS with heat inactivated fetal calf serum (CSL, Sydney, Australia) 10% v/v. The PMNLs were then resuspended in DPBS plus glucose 0.1% w/v (DPBSG), counted on an automated cell counter (Sysmex NE-8000, Sysmex, Kobe, Japan) and adjusted to 2 X lo6 PMNLs/ml. The purity of the preparation was checked and used when > 90% of white blood cells were PMNLs. After PMNLs had been equilibrated for 1 h at 4"C, they were mixed with the Candida suspension at a ratio of 1 Candida cell to every 10 PMNL. The mixture was incubated for 4 h at 37°C with end-over-end rotation and samples were removed at time 0, and after incubation for 1 h and 4 h. A Miles and Misra plate assay was then performed to determine the number of viable Candida cfu. In addition, the numbers of yeast cells in clumps of yeast plus PMNLs was examined microscopically and this number was taken into account when the number of cfu, were calculated in the Miles and Misra assay.
Release of inflammatory mediators
The supernate from the interactions of Candida cells with either PMNLs or platelets were assayed for interleukin-lp (IL-lp), IL-8 and leucotriene 8 4 (LTB4) with commercially available enzyme-linked immunosorbent assay (ELISA) kits obtained from R&D systems, MN, USA (IL-lp, IL-8) and Perspective diagnostics, MA, USA (LTB4). Samples were tested for IL-1p and IL-8 by an antibody sandwich principle. LTB4 was measured by competition inhibition ELISA. The methods for sample preparation and analysis followed protocols supplied by the manufacturers.
Statistical analysis
Correlations between data sets were analysed by Pearson's correlation coefficient.
Results
Interactions of Candida spp. with platelets
All strains, with the exception of C. albicans NCYC 1473, C. albicans NCYC 1467 and C. albicans Y5499, were able to aggregate platelets (Table 1) ; C. tropicalis Y9 aggregated platelets within the shortest incubation time. A Candida cell: platelet ratio of < 1:80 showed either no aggregation, a lag phase of > 25 min, or < 100% aggregation when compared to ADP. At a Candida cell: platelet ratio of 1:80 strains showed minimal lag phase and final percentage aggregation approaching 100%. For the higher ratios, the final percentage aggregations were > 100% indicating that both aggregation and agglutination of platelets was occurring. Thus the optimum Candida cell: platelet ratio for those strains showing aggregation was 1230. Fig. 1 demonstrates the aggregation profile of platelets in the presence of C. tropicalis Y9.
To test for mechanisms of platelet aggregation by Candida spp., several different inhibitors were used with C. tropicalis ( Table 2) . EDTA and imipramine were particularly potent inhibitors of aggregation, and quinacrine and apyrase were moderately antagonistic, reducing the final percentage aggregation to 60% and 35%, respectively. The use of blood fiom different blood group donors did not affect the ability of Candida spp. to aggregate platelets, with Candida cells aggregating platelets from all blood groups.
Two strains, C. albicans (stellatoida) Y523 and C. tropicalis Y9 were killed in the presence of platelets, losing between 40 and 55% viability (Table 3 , Fig. 2 ). C. parapsilosis Y316, C. krusei Y301 and C. ke& Y83 were not killed in the PRP, but could not grow in 
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*Lag phase was the time for the trace to vary from baseline after addition of the Candida. +Percentage aggregation was determined by using the aggregation given by C. tropicalis control (with no inhibitor present) as 100%. 
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Interactions of Candida spp. with complement
All Candida spp. were resistant to the action of complement in serum, and most strains were able to grow after incubation for 4 h (Table 3) . However, C. albicans NCYC 1473, NCYC 1467 and Y5499 and C. keJLr Y83 did not grow in the serum, nor were these strains killed in serum, indicating that these strains were resistant to complement attack but unable to grow in serum. C. albicans NCYC 1473, NCYC 1467 and Y5499 produced hyphae when incubated in serum. 
Survival of Candida spp. in the presence of PMNLs
Three strains were killed in the presence of PMNLs (Table 3) , while all other strains were able to survive. (2) 25 (5) 37 (10) 130 (5) 105 (12) 104 (5) 22 (9) PRP, platelet rich plasma; PMNLs, polymorphonuclear leucocytes; H, hyphal production. *Survival: 100% = the same number of cfu/ml at T = 0 h and T = 4 h; decreasing numbers indicates cell death, increasing numbers indicates cell growth. Survival in the presence of serum is a measure of the ability of strains to evade the complement pathway. Generally, the ability of strains to survive in the IL-8 after incubation for 4 h. Certain strains were able presence of PMNLs mimicked their survival in plateletto induce IL-8 release from platelets. Of the strains rich plasma, and the correlation coefficient was tested, only C. albicans NCYC 1467 and C. albicans statistically significant (p = 0.048).
(stellatoidia) Y523 were able to induce the release of IL-lP from PMNLs. Table 4 shows the production of inflammatory (43) 59 (3) 36 (32) No strain stimulated the release of LTB4 from PMNLs. ND, not determined.
Release of inflammatory mediators
171, it has generally been accepted that whole yeast cells are unable to aggregate platelets whereas cell fragments can [18, 191 . The present study confirms these findings, as C. albicans was the only species unable to aggregate platelets. This study is the first to demonstrate that other species of Candida are able to aggregate platelets. True platelet aggregation was occurring, as the specific inhibitors of platelet aggregation, EDTA that chelates cations, apyrase that reduces the availability of ADP, quinacrine that inhibits the cyclo-oxygenase pathway and imipramine that affects platelet membrane stability, inhibited the aggregation process. Of interest was the fact that platelets derived from different blood group donors were equally able to be aggregated by the yeasts, indicating that blood group sugars are probably not involved in the platelet-Candida interactions, although they are involved in adhesion of Candida spp. to epithelial surfaces [19] .
A recent publication focused attention on the role of complement in the aggregation of platelets by streptococci [lo] , with the assembly of the membrane attack complex (C5b-9) on the surface of the bacteria being hypothesised as a key to allowing platelet aggregation. In conclusion, this study has shown for the first time that non-albicans Candida spp. can aggregate platelets. Certain strains were killed in the presence of platelets, presumably by the release of platelet microbicidal proteins. Furthermore, strains were able to activate complement and activate PMNLs to produce the chemokine IL-8, increasing the recruitment of PMNLs to the site of infection and potentially contributing to tissue destruction by the activation of the PMNLs and release of proteases.
